



The Immuno-Radiotherapy Interest Group

Facts and Enrollment Information

About the Immuno-Radiotherapy Interest Group

- Several studies have demonstrated that radiation can modulate and enhance immune responses to tumors. Hypofractionation or other modifications of standard fractionation may promote immune responses to tumors, but other novel delivery options may also affect several immune responses including T-cell activation and changes in tumor-antigen presentation. However, there is limited understanding of the immunologic impact of hypo- and special multi-fractionated radiotherapy, as these observations are relatively recent. This NCI Interest Group will bring together clinicians and researchers with an interest in radiotherapy and/or immunology to open a dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy.

Goals

- To promote open dialogue on the potential for exploiting radiation-induced immune responses in the context of cancer therapy among radiotherapy and immunology clinicians and researchers.

Interest Group Co-chairs

- Zachary Morris, M.D. (University of Wisconsin, zmorris@humonc.wisc.edu)
- Andrew Sikora, M.D. (Baylor College, andrew.sikora@bcm.edu)
- Samir Khleif, M.D. (Georgetown University, snk48@georgetown.edu)

THE IMMUNO-RADIOTHERAPY INTEREST GROUP

Facts & Enrollment Information

Teleconference Schedule

- The Interest Group meets virtually via the Zoom platform on the first Tuesday of every two months at 3 pm ET – this Interest Group is a merger of RRP’s Radiation and Immunomodulation Interest Group with Immuno-Oncology Translation Network (IOTN) Immuno-radiotherapy Interest Group. The newly merged group is called “Immuno-Radiotherapy Interest Group”.
- The group membership is approximately 50.

Activities and Accomplishments

Clinical Trials:

1. Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer (<https://clinicaltrials.gov/ct2/show/NCT03304639>) (ClinicalTrials.gov Identifier: NCT03304639).
2. Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer – CTEP Project Team Trial (<https://clinicaltrials.gov/ct2/show/NCT02888743>) (ClinicalTrials.gov Identifier: NCT02888743).

Publications

1. A.E. Marciscano, J.M. Walker, H.M. McGee, M.M. Kim, C.A. Kunos, A.M. Monjazeb, S.L. Shiao, P.T. Tran, M.M. Ahmed, Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop, J Immunother Cancer, 6 (2018) 6.

Workshops

1. Radiation and Immunotherapy Leadership Summit: NCI-SITC Bethesda, MD, March 2016 (<https://sitc.sitcancer.org/sitc-meetings/radiationsummit2016/schedule>)
2. Incorporating Radiation Oncology into Immunotherapy: ASTRO-SITC-NCI Workshop. Bethesda, MD, June 2017.

Interested in becoming a member of the RI Interest Group?

- Please Contact the Interest Group Coordinator:

Masoor M. Ahmed, Ph.D.

Radiation Research Program

National Cancer Institute

Division of Cancer Treatment & Diagnosis

Tel: 240 276 5700

Email: mansoor.ahmed@nih.gov